Access the full text.
Sign up today, get DeepDyve free for 14 days.
Yoshihisa Kobayashi, T. Mitsudomi, Y. Sakao, Y. Yatabe (2015)
Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.Annals of oncology : official journal of the European Society for Medical Oncology, 26 1
Chang-Min Choi, Mi Kim, H. Hwang, Jung Lee, W. Kim (2015)
Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.Radiology, 275 1
S. Glantz (1981)
Primer of biostatistics : statistical software program version 6.0
Tsuyoshi Takahashi, M. Sonobe, Masashi Kobayashi, A. Yoshizawa, T. Menju, E. Nakayama, N. Mino, Shotaro Iwakiri, Kiyoshi Sato, R. Miyahara, K. Okubo, T. Manabe, H. Date (2010)
Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion GeneAnnals of Surgical Oncology, 17
(2013)
Metabolic andmetastatic characteristics of ALK-rearranged lung adenocarcinoma
(2014)
Preselection basedonclinical characteristics inGermannon-small-cell lungcancerpatientsscreenedforEML4-ALKtranslocation
K. Kerr, Suzi Mackenzie, S. Ramasami, G. Murray, N. Fyfe, A. Chapman, M. Nicolson, G. King (2004)
Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinomaThe Journal of Pathology, 203
(2010)
Clinicopathologicfeaturesofnon-small-cell lungcancerwithEML4-ALK fusiongene
(1998)
Serum levels of soluble intercellular adhesion moleculeI (ICAMmI, CD54) in patients with non-small-cell lung cancer: correlationwith histological expression of ICAM-I andtumourstage
A. Shaw, B. Yeap, M. Mino‐Kenudson, S. Digumarthy, D. Costa, R. Heist, B. Solomon, Hannah Stubbs, S. Admane, U. McDermott, J. Settleman, Susumu Kobayashi, E. Mark, S. Rodig, L. Chirieac, E. Kwak, T. Lynch, A. Iafrate (2009)
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
A. Tufman, M. Edelmann, F. Gamarra, S. Reu, A. Borgmeier, K. Schrödl, R. Zauber, U. Müller-Lisse, R. Huber (2014)
Preselection Based on Clinical Characteristics in German Non–Small-Cell Lung Cancer Patients Screened for EML4-ALK TranslocationJournal of Thoracic Oncology, 9
(2009)
Clinical features and outcome of patients with non - small - cell lung cancer whoharborEML 4 - ALK
X. Yu, Qingwei Luo, Suzanne Hughes, S. Wade, M. Caruana, K. Canfell, Dianne O'Connell (2014)
Stimulation-induced ectopicity and propagation windows in model damaged axonsJournal of Computational Neuroscience, 37
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
(2013)
Metabolic andmetastatic characteristics of ALK - rearranged lung adenocarcinoma onFDGPET / CT
Jangchul Park, H. Yamaura, Y. Yatabe, W. Hosoda, C. Kondo, J. Shimizu, Y. Horio, Kimihide Yoshida, Kosuke Tanaka, T. Oguri, Yoshihisa Kobayashi, T. Hida (2013)
Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapyCancer Medicine, 3
T. Fukui, Y. Yatabe, Yoshihisa Kobayashi, K. Tomizawa, S. Ito, S. Hatooka, K. Matsuo, T. Mitsudomi (2012)
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.Lung cancer, 77 2
D. Patsios, H Roberts, N Paul, T. Chung, S Herman, A. Pereira, G. Weisbrod (2007)
Pictorial review of the many faces of bronchioloalveolar cell carcinoma.The British journal of radiology, 80 960
D. Planchard, S. Popat, K. Kerr, S. Novello, E. Smit, C. Faivre-Finn, T. Mok, M. Reck, P. Schil, M. Hellmann, S. Peters (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 29 Supplement_4
Shota Yamamoto, R. Korn, R. Oklu, C. Migdal, M. Gotway, G. Weiss, G. Weiss, A. Iafrate, Dong-Wan Kim, M. Kuo (2014)
ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.Radiology, 272 2
Takaaki Sasaki, S. Rodig, L. Chirieac, P. Jänne (2010)
The biology and treatment of EML4-ALK non-small cell lung cancer.European journal of cancer, 46 10
J. Landis, G. Koch (1977)
The measurement of observer agreement for categorical data.Biometrics, 33 1
P. Rhodes (1933)
Administration.British Medical Journal (Clinical research ed.), 286
(2014)
ALK molecular phenotypeinnon–smallcell lungcancer: CTradiogenomic characterization
D. Halpenny, Gregory Riely, S. Hayes, H. Yu, Junting Zheng, C. Moskowitz, M. Ginsberg (2014)
Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?Lung cancer, 86 2
S. Hulley (2013)
Designing clinical research
(2012)
EMA/725670/2012; EMEA/H/C/002489
(2016)
Metastaticnon - small - cell lung cancer : ESMO clinical practice guidelines
S. Rodig, M. Mino‐Kenudson, S. Dacic, B. Yeap, A. Shaw, J. Barletta, Hannah Stubbs, Kenny Law, N. Lindeman, E. Mark, P. Janne, T. Lynch, B. Johnson, A. Iafrate, L. Chirieac (2009)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 15
(2011)
Food-and-drug administration. FDA
Hongyoon Choi, J. Paeng, Dong-Wan Kim, J. Lee, C. Park, K. Kang, June-Key Chung, D. Lee (2013)
Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.Lung cancer, 79 3
R. Rosell, E. Carcereny, R. Gervais, A. Vergnenègre, B. Massutí, E. Felip, R. Palmero, R. García-Gómez, C. Pallarés, J. Sánchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Morán, A. Insa, F. Marinis, R. Corre, I. Bover, A. Illiano, É. Dansin, J. Castro, M. Milella, N. Reguart, G. Altavilla, U. Jiménez, M. Provencio, M. Moreno, J. Terrasa, J. Muñoz-Langa, J. Valdivia, D. Isla, M. Dómine, O. Molinier, J. Mazières, N. Baize, R. García-Campelo, G. Robinet, D. Rodríguez-Abreu, G. López-Vivanco, V. Gebbia, Lioba Ferrera-Delgado, P. Bombaron, R. Bernabé, A. Bearz, Á. Artal, E. Cortesi, C. Rolfo, M. Sánchez-Ronco, A. Drozdowskyj, C. Queralt, I. Aguirre, J. Ramírez, J. Sánchez, M. Molina, M. Taron, L. Paz-Ares (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.The Lancet. Oncology, 13 3
N. Lindeman, P. Cagle, M. Beasley, D. Chitale, S. Dacic, G. Giaccone, R. Jenkins, D. Kwiatkowski, J. Saldivar, J. Squire, E. Thunnissen, M. Ladanyi (2013)
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Archives of pathology & laboratory medicine, 137 6
Y. Li, Yongwen Li, Tong-xin Yang, Sen Wei, Jing Wang, Min Wang, Yuli Wang, Qinghua Zhou, Hongyu Liu, Jun Chen (2013)
Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung CancerPLoS ONE, 8
(2014)
Are there imagingcharac - teristics associatedwith lung adenocarcinomasharboring ALKrearrangements ?
A. Shaw, B. Yeap, B. Solomon, Gregory Riely, J. Gainor, J. Engelman, G. Shapiro, D. Costa, S. Ou, M. Butaney, R. Salgia, R. Maki, M. Varella-Garcia, R. Doebele, Y. Bang, K. Kulig, P. Selaru, Yiyun Tang, K. Wilner, E. Kwak, Jeffrey Clark, A. Iafrate, D. Camidge (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.The Lancet. Oncology, 12 11
A. Grothey, P. Heistermann, S. Philippou, R. Voigtmann (1998)
Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage.British Journal of Cancer, 77
EL Kwak, YJ Bang, DR Camidge (2010)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med, 363
SA Glantz (1997)
Primer of biostatistics
V. Noronha, A. Ramaswamy, V. Patil, A. Joshi, A. Chougule, S. Kane, Rajiv Kumar, A. Sahu, V. Doshi, L. Nayak, A. Mahajan, A. Janu, K. Prabhash (2016)
ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing CountryPLoS ONE, 11
P. Martínez, J. Hernández-Losa, S. Cedres, J. Castellví, A. Martínez-Martí, N. Tallada, N. Murtra-Garrell, Alejandro Navarro-Mendivill, V. Rodríguez-Freixinós, M. Canela, S. Cajal, E. Felip (2013)
Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer PatientsPLoS ONE, 8
N. Lindeman, P. Cagle, M. Beasley, D. Chitale, S. Dacic, G. Giaccone, R. Jenkins, D. Kwiatkowski, J. Saldivar, J. Squire, E. Thunnissen, M. Ladanyi (2013)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular PathologyJournal of Thoracic Oncology, 8
S. Ko, Y. Lee, Jong Park, Y. Cho, H. Yoon, Jin-Haeng Chung, T. Kim, K. Lee, Kwhanmien Kim, S. Jheon, Hyojin Kim, Jae Lee, C. Lee (2014)
Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacityBMC Cancer, 14
R. Siegel, D. Naishadham, A. Jemal (2013)
Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 63
A. Proietti, G. Alí, S. Pelliccioni, C. Lupi, E. Sensi, L. Boldrini, A. Servadio, A. Chella, A. Ribechini, F. Cappuzzo, M. Miccoli, G. Fontanini (2014)
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non–small cell lung cancer: Comparison with histological assessmentCancer Cytopathology, 122
L. Tanoue (2012)
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerYearbook of Pulmonary Disease, 2012
L. West, S. Vidwans, N. Campbell, Jeff Shrager, G. Simon, R. Bueno, P. Dennis, G. Otterson, R. Salgia (2012)
A Novel Classification of Lung Cancer into Molecular SubtypesPLoS ONE, 7
Y. Bang (2011)
The potential for crizotinib in non-small cell lung cancer: a perspective reviewTherapeutic Advances in Medical Oncology, 3
E Thunnissen, L Bubendorf, M Dietel (2012)
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendationsVirchows Arch, 461
Hyojin Kim, S. Jang, D. Chung, S. Yoo, P. Sun, Yan-Xia Jin, K. Nam, J. Paik, Jin-Haeng Chung (2013)
A Comprehensive Comparative Analysis of the Histomorphological Features of ALK-Rearranged Lung Adenocarcinoma Based on Driver Oncogene Mutations: Frequent Expression of Epithelial-Mesenchymal Transition Markers than Other GenotypePLoS ONE, 8
M. Qi, Yanjian Li, Jun Liu, Xiaoqing Yang, Lin Wang, Zhiqiang Zhou, B. Han (2012)
Morphologic Features of Carcinomas With Recurrent Gene FusionsAdvances In Anatomic Pathology, 19
(2014)
Anaplastic lymphoma kinasegenerearrangements incytological samplesofnonsmallcell lungcancer
original report memo (2017) 10:94–102 DOI 10.1007/s12254-016-0305-1 Distinct computed tomography features of non-small- cell lung cancer in a European population with EML4-ALK translocation Ullrich G. Mueller-Lisse · Hanna A. Zimmermann · Carolina Reiners · Simone Reu · Maximilian F. Reiser · Rudolf M. Huber · Amanda Tufman Received: 4 October 2016 / Accepted: 28 November 2016 / Published online: 19 December 2016 © Springer-Verlag Wien 2016 Summary statistical tests (Fisher exact/Student-T) were used to Background Treatment of advanced EML4-ALK- compare ALK-positive and ALK-negative tumors. The translocation-positive non-small-cell lung cancer analyses took potential confounders into account in- (NSCLC) with an ALK tyrosine kinase inhibitor (TKI) cluding patient age, gender, previous NSCLC therapy, is now standard of care. Since EML4-ALK gene fusion UICC stage, and smoking status. is rare in NSCLC and testing depletes both tissue sam- Results Ten of 39 adult European Caucasian patients ples and health care funds, deciding who to screen (age 57 ± 10 years, 17 female) were ALK positive. is critical. CT features associated with EML4-ALK- Diffuse tumor growth (ALK positive 9, ALK negative positive cases may help prioritize individual patients 7/5, p < 0.0005/p < 0.0001, agreement 95%), multiple for ALK testing in settings where
memo - Magazine of European Medical Oncology – Springer Journals
Published: Dec 19, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.